Boston Scientific Acquires Baylis Medical Company Inc.

Boston Scientific Makes $1.5 Billion Investment in MiRus LLC for Option to Acquire TAVR Business

May 18, 2026

Medical Devices

Boston Scientific Corporation invested $1.5 billion for an approximately 34% equity stake in privately held MiRus LLC. Under the investment agreement, Boston Scientific received an exclusive option to acquire MiRus’s SIEGEL balloon-expandable TAVR system business for up to $3 billion in additional cash payments, subject to clinical and regulatory milestones and closing conditions.

Boston Scientific Agrees to Acquire Bolt Medical

January 8, 2025

Medical Devices

Boston Scientific Corporation entered into a definitive agreement to acquire Bolt Medical, Inc., developer of an intravascular lithotripsy (IVL) laser-based platform for treating calcified coronary and peripheral artery disease. The deal includes an upfront payment of about $443 million for the 74% stake Boston Scientific does not already own, plus up to $221 million tied to regulatory milestones.

Boston Scientific Acquires Axonics, Inc.

November 15, 2024

Medical Devices

Boston Scientific agreed to acquire Axonics, a medical technology company focused on urinary and bowel dysfunction, for $71 per share in cash, valuing the equity at approximately $3.7 billion. The boards approved the transaction, which was expected to close in the first half of 2024, and Boston Scientific later announced the acquisition closed on November 15, 2024.

Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B

March 3, 2021

Medical Devices

Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.

Boston Scientific Investment Agreement with Exclusive Option to Acquire Farapulse, Inc.

September 21, 2020

Medical Devices

Boston Scientific Corporation signed an investment agreement that includes an exclusive option to acquire Farapulse, Inc., a privately held developer of pulsed field ablation technology for atrial fibrillation and other cardiac arrhythmias. Farapulse’s system uses irreversible electroporation (pulsed electric fields) to ablate heart tissue without thermal energy. The platform is investigational and not available for sale.

Boston Scientific Acquires BTG plc

August 19, 2019

Medical Devices

Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.